One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Can-Fite BioPharma Ltd. logo
Can-Fite BioPharma Ltd. CANF
$ 1.44 -1.37%
report update icon

Quarterly report 2022-Q4
added 11-18-2026

Can-Fite BioPharma Ltd. Financial Ratios 2025-2011 | CANF

Brief overview of Can-Fite BioPharma Ltd.'s market valuation

Ratios are assessed across five available annual reports in the 2017–2025 interval.

Market valuation is represented by P/E 244.28x (median 129.96x), EV/EBITDA 0.07x (median 0.46x), P/S 11.87x (median 11.87x). Current valuation broadly matches recent historical reference points; the difference from five-year medians is 0%.

The inverse P/E implies an earnings yield of 0.4%. This is not a dividend yield, but current earnings relative to market price.

End-period return metrics are ROE -175.8%, ROA -103.3%, ROCE -146.7%. The business is not generating positive returns on invested resources. Valuation should be read cautiously until earnings recover.

The PEG ratio is 2.81x; investors pay a high price per unit of expected growth.

What the ratios show

Can-Fite BioPharma Ltd.'s multiples form a balanced picture without a clear discount or premium. Future appeal depends on earnings and return trends.

Annual Financial Ratios Can-Fite BioPharma Ltd.

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
-0.5 -0.1 -0.1 -203.7 -51.3 -48.9 -14.6 -106.6 244.3 110.4 149.5 34.6 -4.2 -4.6 -

P/S

11.9 1.6 1.2 2558.0 758.6 925.4 90.9 183.3 1440.0 4561.5 4590.6 - - - -

EPS

-6.0 -10.9 -17.9 -0.0 -0.0 -0.0 -0.1 -0.2 - - - - - - -

EV (Enterprise Value)

-721 K -3.77 M -3.37 M 2.07 B 647 M 701 M 189 M 705 M 1.22 B 782 M 765 M 851 M 36.8 M 28 M 1.61 M

EBITDA per Share

-6.03 -11.2 -19.2 -0.01 -0.02 -0.04 -0.14 -0.14 0.154 0.251 0.221 1.4 -19.3 -17.4 -

EV/EBITDA

0.1 0.5 0.4 -205.2 -43.1 -1.1 -19.2 104.9 242.6 109.0 145.7 34.2 -3.3 -4.2 -

PEG

-0.0 -0.0 -0.0 2.81 0.73 0.85 0.24 1.31 -6.11 5.8 -1.77 0.32 0.42 -0.15 -

P/B

0.5 0.1 0.1 223.2 32.0 116.2 210.9 232.3 399.4 200.2 72.5 123.6 7.8 -36.2 -

P/CF

-0.5 -0.1 -0.1 -191.8 -65.6 -58.5 -16.7 -168.5 -128.0 -86.8 -161.3 -115.5 -4.0 -5.9 -

ROE %

-175.75 -144.96 -122.28 -227.48 -87.71 -237.78 -516.99 -217.94 163.50 181.31 48.50 357.66 -187.11 787.15 -

ROA %

-103.30 -86.40 -76.42 -109.59 -62.29 -151.66 -154.45 -82.63 63.75 69.09 28.78 240.74 -125.73 -340.81 -

ROCE %

-146.69 -115.03 -102.84 -148.89 -73.29 -171.30 -244.89 -112.02 82.74 91.65 32.02 281.75 -200.03 870.47 -

Current Ratio

- - - - - 2.8 1.1 1.6 3.8 4.0 9.9 6.8 3.1 0.7 -

DSO

- - - - - - - - 28.1 46.9 1370.8 - - - -

All numbers in USD currency

Quarterly Financial Ratios Can-Fite BioPharma Ltd.

2025-Q4 2025-Q2 2024-Q4 2024-Q2 2023-Q4 2023-Q2 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

-5.97 - -10.86 - -17.92 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA per Share

-6.03 - -11.2 - -19.2 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROE %

-596.87 -543.40 -488.25 -159.62 -122.28 -61.39 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROA %

-319.68 -292.81 -267.90 -66.82 -76.42 -38.25 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROCE %

-453.22 -409.37 -373.00 -104.04 -102.84 -51.10 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Multiples are an important financial analysis tool for the company Can-Fite BioPharma Ltd., allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
ММЦБ ММЦБ
GEMA
- - - russiaRussia
Lyra Therapeutics Lyra Therapeutics
LYRA
- - $ 24.9 M usaUSA
ОЗОН Фармацевтика ОЗОН Фармацевтика
OZPH
- - - russiaRussia
Промомед Промомед
PRMD
- - - russiaRussia
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
ESSA Pharma ESSA Pharma
EPIX
- - $ 8.86 M canadaCanada
Generation Bio Co. Generation Bio Co.
GBIO
- - $ 344 M usaUSA
Clearside Biomedical Clearside Biomedical
CLSD
- - $ 25.3 M usaUSA
Merus N.V. Merus N.V.
MRUS
- - $ 5.78 B niderlandNiderland
RAPT Therapeutics RAPT Therapeutics
RAPT
- - $ 2.36 B usaUSA
Annexon Annexon
ANNX
$ 3.11 -8.94 % $ 482 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Galapagos NV Galapagos NV
GLPG
- - $ 1.83 B belgiumBelgium
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
- -4.36 % $ 27 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Galmed Pharmaceuticals Ltd. Galmed Pharmaceuticals Ltd.
GLMD
$ 4.63 21.05 % $ 20 M israelIsrael
Achieve Life Sciences Achieve Life Sciences
ACHV
$ 6.78 0.89 % $ 296 M usaUSA
Leap Therapeutics Leap Therapeutics
LPTX
- 368.57 % $ 41.9 M usaUSA
Lumos Pharma Lumos Pharma
LUMO
- - $ 35.3 M usaUSA
Gamida Cell Ltd. Gamida Cell Ltd.
GMDA
- -18.25 % $ 5.04 M israelIsrael
Axcella Health Axcella Health
AXLA
- -16.42 % $ 249 M usaUSA
Metacrine Metacrine
MTCR
- - $ 24.2 M usaUSA
Zealand Pharma A/S Zealand Pharma A/S
ZEAL
- 0.52 % $ 821 M danmarkDanmark
Myovant Sciences Ltd. Myovant Sciences Ltd.
MYOV
- -0.04 % $ 2.62 B usaUSA
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
- -74.18 % $ 955 K usaUSA
Idera Pharmaceuticals Idera Pharmaceuticals
IDRA
- -23.04 % $ 26.6 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Verona Pharma plc Verona Pharma plc
VRNA
- - $ 69.7 B britainBritain
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA
Guardion Health Sciences Guardion Health Sciences
GHSI
- -0.31 % $ 3.64 M usaUSA
Opiant Pharmaceuticals Opiant Pharmaceuticals
OPNT
- - $ 109 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
ImmunoGen ImmunoGen
IMGN
- - $ 7.92 B usaUSA
Vascular Biogenics Ltd. Vascular Biogenics Ltd.
VBLT
- -8.77 % $ 12.4 M israelIsrael
Cidara Therapeutics Cidara Therapeutics
CDTX
- - $ 1.41 B usaUSA
Iterum Therapeutics Iterum Therapeutics
ITRM
- - $ 591 K irlandaIrlanda
Virpax Pharmaceuticals Virpax Pharmaceuticals
VRPX
- -45.12 % $ 2.85 M usaUSA
Navidea Biopharmaceuticals Navidea Biopharmaceuticals
NAVB
- -2.99 % $ 2.47 M usaUSA
Stealth BioTherapeutics Corp Stealth BioTherapeutics Corp
MITO
- - $ 23.9 M usaUSA
OncoSec Medical Incorporated OncoSec Medical Incorporated
ONCS
- 31.87 % $ 1.61 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
bluebird bio bluebird bio
BLUE
- - $ 546 M usaUSA
Landos Biopharma Landos Biopharma
LABP
- 0.58 % $ 144 M usaUSA
CASI Pharmaceuticals CASI Pharmaceuticals
CASI
- - $ 35.4 M usaUSA
ContraFect Corporation ContraFect Corporation
CFRX
- -5.16 % $ 5.39 M usaUSA
Sigilon Therapeutics Sigilon Therapeutics
SGTX
- - $ 728 M usaUSA